Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $10.51 and traded as high as $10.79. Ono Pharmaceutical shares last traded at $10.79, with a volume of 446 shares traded.
Ono Pharmaceutical Stock Performance
The stock has a market cap of $5.27 billion, a price-to-earnings ratio of 16.01 and a beta of 0.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.56 and a current ratio of 3.07. The stock's 50-day simple moving average is $10.47 and its two-hundred day simple moving average is $10.54.
About Ono Pharmaceutical
(
Get Free Report)
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Further Reading
Before you consider Ono Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.
While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
